Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance
- 15 November 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 100 (10) , 3819-3821
- https://doi.org/10.1182/blood-2002-02-0608
Abstract
Translocations involving the immunoglobulin heavy-chain switch region and fibroblast growth factor receptor 3 (FGFR3) are identified in 10% to 15% of patients with myeloma. In previous research we overexpressed FGFR3 or the constitutively active FGFR3-TD mutant in an interleukin-6 (IL-6)–dependent murine myeloma cell line, B9. FGFR3-enhanced IL-6 responsiveness increased phosphorylation of STAT3 and up-regulated Bcl-xL. Since Bcl-xL was up-regulated, we have tested FGFR3-expressing B9 cells for chemotherapy sensitivity. FGFR3 expression did not alter sensitivity to melphalan or doxorubicin. In contrast, B9 cells overexpressing FGFR3 were resistant to treatment with dexamethasone, a phenomenon successfully reversed using a Bcl-xL antisense oligonucleotide. These data demonstrate that the overexpression of FGFR3 in B9 cells confers resistance to dexamethasone but not to anthracyclines or alkylating agents, at least in part through the up-regulation of Bcl-xL. This finding has potential implications for the use of chemotherapy in t(4;14)-positive myeloma.Keywords
This publication has 16 references indexed in Scilit:
- Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)British Journal of Haematology, 2001
- Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myelomaBlood, 2001
- Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor modelInternational Journal of Cancer, 2000
- Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosisBlood, 2000
- Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cellsBritish Journal of Haematology, 1999
- Fluorescence In Situ Hybridization Analysis Shows the Frequent Occurrence of 14q32.3 Rearrangements with Involvement of Immunoglobulin Switch Regions in Myeloma Cell LinesCancer Genetics and Cytogenetics, 1999
- High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridizationGenes, Chromosomes and Cancer, 1999
- Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3Nature Genetics, 1997
- IgH Translocations in Multiple Myeloma: A Nearly Universal Event that Rarely Involves c-mycPublished by Springer Nature ,1997
- Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myelomaProceedings of the National Academy of Sciences, 1996